UK’s NICE Rejects BioMarin’s Drug for Ultra-Rare Metabolic Disorder

The UK’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service (NHS) not offer BioMarin Pharmaceutical’s Vimizim (elosulfase alfa) for treating mucopolysaccharidosis type 4A syndrome, also known as Morquio A syndrome.
Source: Drug Industry Daily